3 Magnificent Growth Stocks to Buy in March
Eli Lilly is one of the top growth stocks in the pharmaceutical industry. Vertex Pharmaceuticals boasts multiple growth ...
Vertex Newly Approved Pain Treatment Lands Higher Cost Tier 3 Placement In UnitedHealth's Optum Rx Formularies
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
MoneyWeek on MSN1d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseases
Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...
Healthcare Dive26d
A new, non-opioid pain drug is here. Getting it to patients could be agony.
Expectations around Journavx are high. With the U.S. still mired in an overdose crisis that’s killed hundreds of thousands of people, Vertex is positioning its medicine as a valuable alternative ...
2 Minute Medicine4d
Vertex: non-opioid pain reliever Journavx shows success in post operative pain control
In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated statistically significant reductions in acute surgical pain over 48 hours ...
5 Top Stocks to Buy in March
U.S.-based companies are dragging down the major stock market indexes. Here's why four Motley Fool contributors think chip ...
Vertex Pharmaceuticals Leads 3 Value Stocks Offering Estimated Intrinsic Value
As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value ...